ScholarWorks@SUNGKYUNKWAN UNIVERSITY: KIM, JONG MAN

Detailed Information

KIM, JONG MAN (김종만)

Medicine (Medicine)

Research Area

Tel
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Hepatocellular carcinoma:51||Liver transplantation:47||Hepatectomy:20||liver transplantation:17||Survival:16||hepatocellular carcinoma:14||Recurrence:14||Liver Transplantation:13||Laparoscopy:11||Radiofrequency ablation:9||Immunosuppression:8||Tumor recurrence:8||Living donor liver transplantation:8||Hepatitis B virus:8||survival:7||Treatment outcome:7||Magnetic resonance imaging:6||Tacrolimus:6||Prognosis:6||immunosuppression:6||Laparoscopic liver resection:6||Living donors:5||Kidney transplantation:5||Carcinoma, hepatocellular:4||Outcome:4||Intrahepatic cholangiocarcinoma:4||Liver:4||living donors:4||Milan criteria:4||Carcinoma:4||prognosis:4||Renal insufficiency:4||Living Donors:4||regional anesthesia:3||Hepatitis C virus:3||Microvascular invasion:3||Ultrasonography:3||living donor liver transplantation:3||Alphafetoprotein:3||Graft survival:3||Guidelines:3||outcome:3||outcomes:3||Rejection:3||Risk factors:3||Hepatic veins:3||Surgery:3||hepatocellular:3||COVID19:3||tacrolimus:3||Diagnosis:3||Management:3||laparoscopic liver resection:3||Transplantation:3||41BB:2||Complications:2||Hepatic resection:2||Open liver resection:2||efficacy:2||Liver regeneration:2||Liver resection:2||HBV reactivation:2||Aged:2||recurrence:2||Organ transplantation:2||Tuberculosis:2||acute liver failure:2||renal dysfunction:2||Calcineurin antagonists:2||Overall survival:2||Living donor:2||tumor recurrence:2||YMDD mutation:2||Thrombosis:2||Pediatric:2||Surgical outcomes:2||safety:2||Diaphragm:2||microvascular invasion:2||Hepatocellular carcinoma (HCC):2||kidney transplantation:2||Minimally invasive surgical procedures:2||Gadoxetic acid:2||Chemoembolization:2||Minimally invasive surgery:2||Minimal invasive surgery:2||Local tumor progression:2||Entecavir:2||thrombectomy:2||Postoperative complications:2||Vaccination:2||Tenofovir:2||transplantation:2||livingdonor liver transplantation:2||Erector spinae plane block:2||Resection:2||Incidence:2||Neoplasm recurrence:2||MELD score:2||portal vein thrombosis:2||Liver cirrhosis:2||Deceased donor liver transplantation:2||Safety:2||Renal transplantation:2||Sarcopenia:2||HBV replication:1||HCC:1||HMGCoA Reductase Phosphatise:1||Hemodialysis:1||Hepacivirus:1||Hepatitis B Immunoglobulin:1||Hepatitis B Virus:1||Hepatitis B core antibody:1||Hepatitis B immunoglobulin:1||Hepatocellular:1||Hepatocellular Carcinoma:1||Hepatocellular adenoma:1||Hepatocellular ca:1||Herpes Zoster:1||Herpes zoster:1||Hospital Mortality:1||Human leukocyte antigen:1||Humans:1||Immunologic desensitization:1||Immunosuppressive agents:1||Immunotherapy:1||Infection:1||Interferongamma release assay:1||Interferongamma releasing assay:1||Intestinal obstruction:1||Invasive aspergillosis:1||Isoniazid:1||Key Words:1||Kidney donation:1||Kidney failure:1||Kidney transplantatio:1||LC3:1||LIRADS:1||Laparoscopic hepatectomy:1||Laparoscopic left hepatectomy:1||Laparoscopic living donor hepatectomy:1||Laparoscopic surgery:1||Laparoscopic surgical procedures:1||Largeforsize syndrome:1||Latent tuberculosis:1||Latent tuberculosis infection:1||Learning curve:1||Left lateral segment:1||Live donor:1||Live liver donor:1||Liver Cancer:1||Liver Imaging Reporting and Data System:1||Liver Neoplasms:1||Liver disease:1||Liver function test:1||Liver metastasis:1||Liver neoplasms:1||Living Donor Liver Transplantation:1||Living donor liver transplant:1||Livingdonor liver transplantation:1||Local:1||Local neoplasm recurrence:1||Lung lobectomy:1||Lymphocytotoxic crossmatch:1||M2BPGi:1||Mechanical ventilator:1||Metasta:1||Micafungin:1||Microbubbles:1||Middle hepatic vein reconstruction:1||Milan criteria (MC):1||MoRAL score:1||Model for EndStage Liver Disease:1||Model for endstage liver disease score:1||Mortality:1||Multicenter study:1||Multidisciplinary:1||Multimodal analgesia:1||Multinodular lesion:1||Multiple myeloma:1||Multiplicity:1||Murine colon cancer metastasis model:1||Natural killer cells:1||Necrosis:1||Neutrophil to lymphocyte ratio:1||Nomogram:1||Nonanatomic resection:1||Older:1||Oncedaily:1||Open conversion:1||Open left hepatectomy:1||Operation:1||Opportunistic infections:1||Optimal T cell activation:1||Organ harvesting:1||Outcomes:1||Pain:1||Paranasal aspergilloma:1||Partial hepatectomy:1||Pediatrics:1||Pericardiac tamponade:1||Peritoneal fibrosis:1||Placenta:1||Pneumatosis intestinalis:1||Pneumonia:1||Portal Vein Flow Modulation:1||Portal vein:1||Portal vein tumor thrombosis:1||Postoperative:1||Postoperative care:1||Postoperative mortality:1||Postoperative pain:1||Prediction:1||Preoperative period:1||Prevention and control:1||Primary graft dysfunction:1||Prolongedrelease tacrolimus:1||Propensity score:1||Propensity score match:1||Prophylaxis of invasive fungal infection:1||Protein induced by vitamin K antagonistII:1||Psychology:1||Pulmonary aspergillosis:1||Quadratus lumborum block:1||Quality of Life:1||Radiation therapy:1||Radiotherapy:1||RealTime Polymerase Chain Reaction:1||Recurrencefree survival:1||Regional anesthesia:1||Rehabilitation:1||Rejecti:1||Renal dysfunction:1||Reoperation:1||Republic of Korea:1||Right posterior sectionectomy:1||Risk factor:1||Rupture:1||SARSCoV2:1||Satellite nodule:1||Septic shock:1||Short Physical Performance Battery:1||Simultaneous liver resection:1||Skeletal muscle:1||Small hepatocellular carcinoma:1||SmallforSize Syndrome:1||Smallforsize graft:1||Smallforsizesyndrome:1||Stage:1||Stage IIIA:1||Steatosis:1||Stents:1||Streamline flow:1||Stricture:1||Surgical adhesion:1||Surveillance:1||Surveys:1||Systemic inflammation:1||TLymphocyte Subsets:1||TACE:1||TNFα:1||Therapeutic embolization:1||Therapeutic equivalence:1||Thigh:1||Tissue and organ procurement:1||Tissue donors:1||Treatment:1||Tuberculosis pericarditis:1||Tumor Marker:1||Tumor biology:1||Tumor biomarker:1||Tumor marker:1||Tumor size:1||Tumorinfiltrating lymphocytes:1||Undifferentiated sarcoma:1||Unrelated Donors:1||Validation:1||Venous thrombosis:1||Viral Hepatitis:1||Virtual reality:1||Washout:1||Watery diarrhea:1||Wound complication:1||aborted liver transplantation:1||abortion of liver transplantation:1||alcholic liver disease:1||analgesia:1||anatomical resection:1||anatomical resection (AR):1||androgen receptor:1||antibodymediated rejection:1||antineoplastic hormonal drug:1||autologous:1||benchmarks:1||bile duct resection:1||bile duct tumor thrombus:1||biliary stricture:1||blood transfusion:1||bowel necrosis:1||bridge therapy:1||carcinogenesis:1||changes of liver enzymes:1||chronic kidney disease:1||complications:1||contrast agent:1||cytomegalovirus:1||cytomegalovirus pp65 antigen:1||depression:1||different etiology:1||disease burden:1||emerging markets:1||epidemiology:1||erector spinae plane block:1||estrogen:1||family support:1||filtration:1||fulminant:1||gene signatures:1||glucose metabolism:1||graft rejections:1||graft steatosis:1||growth:1||hepatectomy:1||hepatitis B virus:1||highvolume plasma exchange:1||illustration:1||image guidance:1||immune monitoring:1||immunomodulation:1||immunotherapy:1||incidence:1||initial treatment:1||insulin sensitivity:1||intraoperative blood sal:1||intraoperative hemodynamic instability:1||intrathecal morphine:1||ischemia&:1||jaundice:1||laparoscopic hepatectomy:1||laparoscopic living donor hepatectomy:1||laparoscopic right hemihepatectomy:1||laparoscopic right posterior sectionectomy:1||laparoscopy:1||leukocyte reduction:1||lipid metabolism:1||liposarcoma:1||liver cancer:1||liver donor:1||liver metastatic colon cancer model:1||liver resection:1||liver transplantation recipients:1||living donor:1||living donor right lobe liver transplantation:1||living liver donors:1||locoregional neoplasm:1||locoregional therapy:1||locoregional treatment:1||long term:1||mTOR:1||mTOR inhibitor:1||magnetic resonance imaging:1||metastasis:1||morbidity:1||mortality:1||mycophenolate mofetil:1||no go hepatectomy:1||non B non C:1||noncirrhosis:1||nonsmall cell lung cancer:1||open conversion:1||opioids, adverse effects:1||organ transplantation:1||overall survival:1||oxidative stress:1||p22FLIP:1||pain outcome measurement:1||pain, postoperative:1||partial liver graft:1||patient blood management:1||pediatric:1||perfusion:1||pharmacokinetics:1||portal vein complication:1||portal vein tumor thrombus:1||positron emission tomography (PET):1||postoperative analgesia:1||prognostic factor:1||protocol:1||pulmonary hypertension:1||pure laparoscopic donor right hepatectomy:1||quadratus lumborum block:1||questionnaires:1||radiofrequency ablation:1||radiotherapy:1||rapamycin:1||reexploration:1||recurrences:1||relapse:1||renal function:1||reperfusion injury:1||resection:1||retroperitoneal space:1||right hemihepatectomy:1||risk factors:1||rituximab:1||ropivacaine:1||sexual dimorphism:1||sleep quality:1||smoking:1||solid organ transplantation:1||sorafenib:1||surgery:1||surgical resection:1||symptom experience:1||systematic review:1||time to progression:1||timeconditional propensity score:1||tissue expansion devices:1||treatment outcome:1||tumor biology:1||tumor microenvironment:1||tumor size:1||venous congestion:1||간이식:1||멜드 점수:1||신장이식:1||심장사 후 장기기증:1||이식편 생존율:1||#8208:1||장기배정:1||3hydroxy3methylglutarylcoenzyme A:1||3D modeling:1||3D printer:1||3D printing:1||3d printer:1||3d printing:1||41BB monoclonal antibody:1||ABO incompatible:1||ABOincompatib:1||Abortion:1||Activationinduced cell death:1||Acute liver failure:1||Acute on chronic liver failure:1||Acute rejection:1||Acuteonchronic liver failure progression:1||Adherence:1||Adjuvant radiotherapy:1||Alcohol relapse:1||Alcoholrelated liver disease:1||Allocation:1||Aminotransferase:1||Anatomic resection:1||Angiosarcoma:1||AntiSARSCoV2 S Antibody:1||Antioxidative stress:1||Antitumor effects:1||Antifungal agents:1||Antiviral Agent:1||Antiviral agents:1||Artificial intelligence:1||Asia:1||Aspartate aminotransferasetoplatelet ratio index:1||Autoantibody:1||Autophagy:1||Bacteremia:1||Beclin1:1||Biliary:1||Biliary atresia:1||Biochemical tumor markers:1||Biomarker:1||Biomarkers, tumor:1||Body mass index:1||Brain death:1||Brain death donor:1||Creactive protein:1||CCI<sup>®</sup>:1||CT:1||Calcineurin inhibitors:1||Carcinogenesis:1||Catheter ablation:1||Chest image:1||Children:1||Chimerism:1||Cholangiocarcionoma:1||Cirrhosis:1||Clinical practice guideline:1||Colon cancer:1||Color:1||Colorectal cancer with liver metastases:1||Colorectal liver metastasis:1||Comparison:1||Computed tomography:1||Contrast media:1||Conversion to open surgery:1||Culture techniques:1||Curative hepatectomy:1||Cytokine:1||Cytomegalovirus Infections:1||Cytomegalovirus infection:1||DC vaccine:1||De novo hepatitis B virus:1||Decision Making:1||Deep learning:1||Delayed graft function:1||Diabetes:1||Donation after circulatory death:1||Donor complication:1||Doppler:1||EASL:1||Early Detection:1||Early allograft dysfunction:1||Early recurrence:1||Education:1||Efficacy:1||Elderly:1||Endoscopic:1||Equipoise:1||Ethics:1||Extracellular contrast:1||Extracorporeal membrane oxygenation:1||FDG PET:1||Fatigue:1||Fibrosis4 index:1||Fluconazole:1||Frailty:1||Fungemia:1||Glissonian approach:1||Grade:1||Graft Inflow Modulation:1||Graft Rejection:1||Graft Survival:1||Graft outcome:1||Graft vs Host Disease:1||Graftversushost disease:1||

STATISTICS: Total View :5,228,312; Today View :197

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREAsamsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE